At APA, Neuronetics Launches TMS
Executive Summary
For millions of Americans who suffer from moderate to severe depression-and millions more around the world-existing drug therapies don't provide adequate treatment. For some, the drugs simply don't work; for others, the drugs treat their depression, but their side effects are so debilitating that the cure is worse than the disease. Now, Neuronetics says it has a new approach to depression treatment, one based on the focused delivery of magnetic energy, that works for these otherwise untreatable patients. More importantly, the company claims, it now has the data to prove it.
You may also be interested in...
Neuronetics Inc.
Neuronetics Inc. has developed a device for treating serious depression in pharmaco-resistant patients. The company believes that its repetitive Transcranial Magnetic Stimulation technology, delivered noninvasively in an outpatient setting, is free of the serious side effects that accompany antidepressant drugs; moreover that it will be more effective and much safer for patients than the only currently approved neuromodulation technology for depression: electroconvulsive therapy.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.